Virometix Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$7.93M
- Investors
-
2
Virometix General Information
Description
Developer of vaccines and immunotherapeutic drugs designed to prevent and treat infections and chronic human diseases. The company's vaccines and immunotherapeutic drugs integrate rational molecular design, chemical synthesis, and proprietary synthetic particle technology for rapid production and optimization, enabling doctors and physicians to combat newly arising complex viral and bacterial pathogens.
Contact Information
Website
www.virometix.comCorporate Office
- Wagisstrasse 14
- 8952 Schlieren
- Switzerland
Corporate Office
- Wagisstrasse 14
- 8952 Schlieren
- Switzerland
Virometix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 16-Jul-2020 | $7.93M | Completed | Clinical Trials - General | ||
| 6. Later Stage VC | Completed | Clinical Trials - General | ||||
| 5. Later Stage VC (Series A) | 05-Sep-2017 | Completed | Clinical Trials - General | |||
| 4. Seed Round | 15-Oct-2015 | Completed | Clinical Trials - General | |||
| 3. Seed Round | 28-Nov-2014 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 01-Sep-2009 | $9.4K | $9.4K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2009 | Completed | Startup |
Virometix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Ordinary shares | ||||||||
| Ordinary shares | ||||||||
| Ordinary shares | 282,360 | $0.105694 | $3.09 | $3.09 | 1x | $3.09 | 2.29% | |
| Ordinary shares | 306,140 | $0.105694 | $2.16 | $2.16 | 1x | $2.16 | 2.48% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Virometix Comparisons
Industry
Financing
Details
Virometix Competitors (63)
One of Virometix’s 63 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
| Anaveon | Venture Capital-Backed | Basel, Switzerland | ||||
| Centrose | Venture Capital-Backed | Middleton, WI | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD |
Virometix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Virometix Patents
Virometix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4216992-A1 | Particle comprising an rsv-f protein for use in rsv vaccination | Pending | 28-Sep-2020 | ||
| US-20230355737-A1 | Particle comprising an rsv-f protein for use in rsv vaccination | Pending | 28-Sep-2020 | ||
| CA-3121724-A1 | Lipopeptide building blocks and synthetic virus-like particles | Pending | 20-Dec-2018 | ||
| US-20220054619-A1 | Lipopeptide building blocks and synthetic virus-like particles | Pending | 20-Dec-2018 | ||
| EP-3897708-A1 | Lipopeptide building blocks and synthetic virus-like particles | Pending | 20-Dec-2018 | A61K39/12 |
Virometix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Virometix Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Venture Kick | Accelerator/Incubator | Minority | ||
| University of Zürich | University |
Virometix FAQs
-
When was Virometix founded?
Virometix was founded in 2009.
-
Where is Virometix headquartered?
Virometix is headquartered in Schlieren, Switzerland.
-
What is the size of Virometix?
Virometix has 15 total employees.
-
What industry is Virometix in?
Virometix’s primary industry is Drug Discovery.
-
Is Virometix a private or public company?
Virometix is a Private company.
-
What is the current valuation of Virometix?
The current valuation of Virometix is .
-
What is Virometix’s current revenue?
The current revenue for Virometix is .
-
How much funding has Virometix raised over time?
Virometix has raised $18.8M.
-
Who are Virometix’s investors?
Venture Kick and University of Zürich have invested in Virometix.
-
Who are Virometix’s competitors?
Mabworks Biotech, Light Chain Bioscience, Anaveon, Centrose, and NexImmune are some of the 63 competitors of Virometix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
